Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis

• Status: Completed
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the long-term efficacy and safety of FK506 ophthalmic suspension in patients with vernal keratoconjunctivitis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: Tacrolimus

Criteria

Inclusion Criteria:

• Vernal keratoconjunctivitis patients who were enrolled in the FJ-506D-AC09 study

• Patients who wish to receive continuous administration of FK506 ophthalmic suspension

Exclusion Criteria:

• Subjects who needed prohibited concomitant therapy at the initiation of the study

• Subjects who needed to wear contact lenses during treatment period on a testing eye

• Subjects with complicating an eye infection